Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoid Interstitial Pneumonia 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1DNA Repair-Deficiency Disorders 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Clinical Stage I Gastric Cancer AJCC v8 1Cholangiocarcinoma 1

Interventions

Gemcitabine 11Magnetic Resonance Spectroscopy 10Specimen Handling 8Cisplatin 7pembrolizumab 6Radiation 5Mitomycin 4Fluorouracil 4Cystoscopy 4enfortumab vedotin 3durvalumab 3dehydroftorafur 3avelumab 3Transurethral Resection of Bladder 3Radiotherapy 3Platinum 3Nivolumab 3Mitozytrex 3Cystectomy 31,2-diaminocyclohexaneplatinum II citrate 3ulixertinib 2tremelimumab 2erdafitinib 2atezolizumab 2Paclitaxel 2Immunoglobulin G 2Docetaxel 2Disulfides 2Carboplatin 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × dehydroftorafur × 30 days × Clear all
NCT06770582 2026-06-03

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
160 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03775265 2026-05-29

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
475 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04216290 2026-05-22

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
11 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡